These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36291640)

  • 1. Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy.
    Errico F; Marino C; Grimaldi M; Nuzzo T; Bassareo V; Valsecchi V; Panicucci C; Di Schiavi E; Mazza T; Bruno C; D'Amico A; Carta M; D'Ursi AM; Bertini E; Pellizzoni L; Usiello A
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy.
    Panicucci C; Sahin E; Bartolucci M; Casalini S; Brolatti N; Pedemonte M; Baratto S; Pintus S; Principi E; D'Amico A; Pane M; Sframeli M; Messina S; Albamonte E; Sansone VA; Mercuri E; Bertini E; Sezerman U; Petretto A; Bruno C
    Cell Mol Life Sci; 2024 Sep; 81(1):393. PubMed ID: 39254732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
    Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
    J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
    Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
    Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients.
    Nuzzo T; Russo R; Errico F; D'Amico A; Tewelde AG; Valletta M; Hassan A; Tosi M; Panicucci C; Bruno C; Bertini E; Chambery A; Pellizzoni L; Usiello A
    Commun Med (Lond); 2023 Feb; 3(1):28. PubMed ID: 36792810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nusinersen: First Global Approval.
    Hoy SM
    Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.
    Garofalo M; Bonanno S; Marcuzzo S; Pandini C; Scarian E; Dragoni F; Di Gerlando R; Bordoni M; Parravicini S; Gellera C; Masson R; Dosi C; Zanin R; Pansarasa O; Cereda C; Berardinelli A; Gagliardi S
    Biol Direct; 2023 Sep; 18(1):57. PubMed ID: 37705059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
    Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
    Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen: A Treatment for Spinal Muscular Atrophy.
    Claborn MK; Stevens DL; Walker CK; Gildon BL
    Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
    Li Q
    Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy.
    Zhang Q; Hong Y; Brusa C; Scoto M; Cornell N; Patel P; Baranello G; Muntoni F; Zhou H
    Sci Rep; 2024 Oct; 14(1):23491. PubMed ID: 39379509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep architecture and Nusinersen therapy in children with Spinal Muscular Atrophy type 1.
    Verrillo E; Pavone M; Bruni O; Ferri R; Chiarini Testa MB; Cherchi C; D'Amico A; Cutrera R
    Sleep Med; 2023 Oct; 110():106-110. PubMed ID: 37572575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
    Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
    Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.